Cardiac aging is a gradual process: even though heart problems typically become obvious in late life, the underlying damage starts accumulating in middle age. One key culprit is endoplasmic reticulum (ER) stress—a form of cellular dysfunction where protein-folding machinery overwhelms and triggers inflammation and damage. Previous work by this group showed that ER stress gradually increases through middle age and peaks in very old hearts, and that metformin (a common diabetes drug) can reverse some of this damage in late-stage aging. The unanswered question: can metformin protect hearts *before* the damage becomes severe?
To test this, the team used 18-month-old mice—equivalent to humans in their 50s—as a model of early cardiac aging. They gave some mice metformin in drinking water for two weeks, then exposed all mice to isoproterenol (ISO), a drug that mimics heart attack-like stress by increasing heart workload. They measured cardiac function and mitochondrial respiration (how well the cell's energy factories work) across the stress and recovery period.
The results support the hypothesis: metformin-treated mice showed significantly better cardiac performance after ISO stress compared to untreated controls. Crucially, metformin-treated hearts also maintained better mitochondrial respiration, suggesting the drug protected the machinery that powers heart cells. The mechanism appears to involve reducing baseline ER stress even before the stress challenge occurred.
However, this is an animal study with a relatively small sample size (18 mice total), so caution is warranted. Animal models don't always translate to humans—drug dosing, metabolism, and the complexity of human aging differ substantially. The study also doesn't specify whether mice were male or female (sex differences in cardiac aging are well-documented), and there's no data on long-term outcomes beyond the acute recovery period. The one-dose-fits-all approach (metformin in drinking water) also doesn't mirror real clinical dosing in humans.
For longevity research, this finding is encouraging because it suggests metformin might work as a preventive intervention in middle age, not just as a rescue treatment in advanced age. If replicable in larger animal studies and eventually in human trials, this could position metformin as a 'geroprotector'—a drug that slows aging processes before overt disease appears. Notably, metformin is already widely used, inexpensive, and has a long safety record, making it an attractive candidate for repurposing studies.
The next logical step would be replication in independent labs, longer-term follow-up studies, and eventually human trials in middle-aged populations at risk for cardiovascular disease.
0 Comments
Log in to join the discussion.